Skip to Main Content

Acadia Pharmaceuticals’ (ACAD) share price has flagged since an April story by CNN that highlighted serious and sometimes fatal side effects tied to Nuplazid, its recently approved treatment for symptoms of Parkinson’s disease. Now FDA Commissioner Scott Gottlieb has promised to “go back and take another look.”

And that could mean bringing Nuplazid in front of another FDA advisory panel, which would allow outside experts to take a second, closer look at the drug’s safety profile.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!